How to Help Your Patients Save Money on Yusimry: A Provider's Guide to Savings Programs

For providers prescribing Yusimry (adalimumab-aqvh), cost is a real barrier for many patients — even though Yusimry is the lowest-list-price adalimumab biosimilar on the market. Understanding the savings landscape allows your team to intervene proactively and prevent treatment interruption due to cost. This guide covers every savings program and strategy available in 2026, organized by patient type.

Why Cost Is Still a Challenge With Yusimry

Yusimry launched in July 2023 at $995 per carton — approximately 85% less than Humira's list price of roughly $6,922 per carton. In employer claims data from 2024, Yusimry averaged $639 per prescription — the lowest among all adalimumab biosimilars analyzed. On paper, it's the most affordable option.

But Yusimry lacks private-label deals with the three major PBMs (CVS Caremark, Express Scripts, OptumRx), which means it often sits on a non-preferred tier — triggering higher cost-sharing, prior authorization requirements, and step therapy mandates. The result: patients may face higher actual costs than the list price suggests, or have difficulty accessing Yusimry at all through their insurance.

For Commercially Insured Patients: The Yusimry Solutions Copay Card

The primary savings tool for commercially insured patients is the Yusimry Solutions Copay Card, offered by Coherus BioSciences:

Benefit: Reduces patient out-of-pocket cost to as little as $0 per prescription

Maximum savings: $100 per 28-day supply

Eligibility: Must have commercial (employer or marketplace) insurance; NOT available for Medicare, Medicaid, or other federal programs

How to enroll: Patient calls 1-800-987-4679 or visits patient.yusimry.com/cost-of-yusimry. Ask your doctor to facilitate enrollment at the point of prescribing.

Provider action: Train your medical assistant or front desk staff to mention the copay card when giving patients a Yusimry prescription. Many patients are unaware of copay assistance programs. A quick 30-second mention at checkout can make the difference between a patient who fills their prescription and one who doesn't.

For Uninsured or Underinsured Patients: Cost Plus Drugs

For patients without insurance, with Medicare or Medicaid (who can't use the copay card), or with high-deductible plans where they pay full cost until their deductible is met, Cost Plus Drugs is the most practical option:

Price: $569.27 per 2-pen carton (a monthly supply for most indications) plus dispensing and shipping fees

Requires: Valid prescription — you can e-prescribe directly to costplusdrugs.com

How it works: Patient orders online, Cost Plus Drugs ships to their door within a few days

Provider action: Add costplusdrugs.com to your e-prescribing system as a pharmacy option. When a patient has insurance barriers or cannot access Yusimry through traditional channels, sending the prescription to Cost Plus Drugs is a reliable fallback that takes minutes.

For Medicare Patients: Part D Navigation

Medicare patients cannot use manufacturer copay cards (federal anti-kickback rules). However, Medicare Part D does cover specialty biologics including Yusimry. Key 2026 Medicare Part D considerations:

$2,100 annual out-of-pocket cap: As of 2026, Medicare Part D has a $2,100 out-of-pocket maximum. Once a patient reaches this cap, covered medications are 100% paid by the plan for the rest of the year. This is significant for specialty biologic patients.

Extra Help / LIS: Medicare beneficiaries with limited income may qualify for the Low Income Subsidy (Extra Help) program, which significantly reduces Part D costs — including specialty drug copays.

Plan comparison: Use Medicare.gov's plan finder tool to help Medicare patients compare Part D plans based on Yusimry (or preferred biosimilar) coverage and cost.

For Patients Who Can't Get Yusimry Covered: The Strategic Alternative Approach

If Yusimry remains inaccessible or cost-prohibitive for a patient despite all savings programs, prescribing the formulary-preferred adalimumab biosimilar is a clinically valid strategy. Clinical evidence, including the NOR-SWITCH trial, confirms that switching between adalimumab products is safe — no meaningful loss of efficacy or increase in adverse events. Formulary-preferred options (Amjevita, Cyltezo, Hyrimoz) often come with $0 copay for commercially insured patients on the relevant PBM's plan.

Quick Reference: Savings Programs for Yusimry Patients

Commercially insured: Yusimry Solutions Copay Card → $0/rx; call 1-800-987-4679

Uninsured / underinsured / HDHP: Cost Plus Drugs → $569.27/carton + fees; costplusdrugs.com

Medicare Part D: $2,100 annual OOP cap; Extra Help/LIS for low income; no copay cards

Patient assistance: Contact Coherus at 1-800-987-4679; NeedyMeds.org and RxAssist.org can identify additional programs

Formulary barrier? Consider prescribing formulary-preferred adalimumab biosimilar; switching is clinically safe

For help locating pharmacies that carry Yusimry for your patients, visit medfinder.com/providers. Also see our full provider guide: How to Help Your Patients Find Yusimry in Stock.